Tarek Ahdab, MD
Interventional Cardiology · Rockford, ILNPI 1184849747
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,047 of the $4,990 with a category attached, or 61.0%. 22 manufacturers reported payments, led by Bard Peripheral Vascular, Inc. at 34.8% of the total. Reporting peaked in 2019 at $1,744 and has fallen 97.3% since, to $47 in 2025. That places this record below the midpoint for interventional cardiology clinicians in IL, where the typical reported total is $7,434.
Across 171 payments — averaging $29.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bard Peripheral Vascular, Inc.$2K
- Avinger Inc.$856
- Johnson & Johnson$604
- E.r. Squibb & Sons, L.L.C.$287
- Novartis$262
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$192
- plus $1K from 16 others
What the payments were for
- Travel & lodging$1,87938%
- Food & beverage$3,04761%
- Education$641%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bard Peripheral Vascular, Inc. | 13 | $1,734 |
| Avinger Inc. | 4 | $856 |
| Johnson & Johnson | 48 | $604 |
| E.r. Squibb & Sons, L.L.C. | 20 | $287 |
| Novartis | 17 | $262 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 14 | $192 |
| Boston Scientific | 7 | $182 |
| Amgen | 8 | $152 |
| Medtronic(2 entities) | 8 | $136 |
| Pfizer | 5 | $114 |
| AstraZeneca | 7 | $103 |
| Boehringer Ingelheim | 5 | $90 |
| Amarin Pharma, Inc. | 3 | $61 |
| Esperion Therapeutics, Inc. | 3 | $56 |
| Terumo Medical Corporation | 2 | $32 |
| Edwards Lifesciences | 1 | $23 |
| Portola Pharmaceuticals, LLC | 1 | $23 |
| Lantheus Medical Imaging, Inc. | 1 | $21 |
| Abbott | 1 | $18 |
| Angiodynamics, Inc. | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $14 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RotarexS 6 F x 135 cm$1,148
- PANTHERIS$708
- Crosser iQ$353
How this compares
$4,990 in reported general payments places this provider in the 35th percentile of 303 interventional cardiology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 139 | $148,861 |
| XareltoRivaroxaban | 121 | $133,639 |
| EntrestoSacubitril/Valsartan | 74 | $86,740 |
| JardianceEmpagliflozin | 60 | $73,186 |
| Repatha SureclickEvolocumab | 76 | $51,583 |
| MultaqDronedarone Hcl | 13 | $21,375 |
| BrilintaTicagrelor | 15 | $19,331 |
| Praluent PenAlirocumab | 21 | $14,143 |
| Repatha SyringeEvolocumab | 20 | $8,742 |
| VascepaIcosapent Ethyl | 11 | $5,665 |
| Ezetimibe | 122 | $4,170 |
| Rosuvastatin Calcium | 154 | $2,704 |
| Ranolazine ErRanolazine | 18 | $2,544 |
| Atorvastatin Calcium | 241 | $2,377 |
| ClopidogrelClopidogrel Bisulfate | 146 | $1,894 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $114 | $148,861139 claims |
| Johnson & JohnsonXarelto | $604 | $133,639121 claims |
| NovartisEntresto | $262 | $86,74074 claims |
| Boehringer IngelheimJardiance | $90 | $73,18660 claims |
| AstraZenecaBrilinta | $103 | $19,33115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 303 interventional cardiology providers in Illinois.
Other interventional cardiology in Rockford
- Jan SkowronskiRockford$41K
- Andrei PopElk Grove Village$900K
- Atman ShahChicago$788K
- Ravi RamanaPalos Park$458K
- Mahesh RajuDowners Grove$281K
- Mark RicciardiEvanston$253K
- Neal SawlaniPark Ridge$246K
- Tony de MartiniSpringfield$208K
- Bouyella ReddyMoline$172K
- David StewartChicago$169K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.